



*Better health through
laboratory medicine.*

PEARLS OF LABORATORY MEDICINE

Hypercalcemia: Causes and Laboratory Investigation

Qing H. Meng PhD, MD, DABCC, FCACB
Section Chief of Clinical Chemistry Laboratories
Professor
Department of Laboratory Medicine
The University of Texas MD Anderson Cancer Center




Outline


- ❑ Provide brief review on calcium homeostasis
- ❑ Discuss causes of hypercalcemia
- ❑ Identify laboratory approach to hypercalcemia



Distribution of Calcium



Calcium Homeostasis



Regulation of Calcium Homeostasis

Hormones	Effect on bones	Effect on intestine	Effect on kidneys	Blood level
PTH	↑ Bone resorption	↑ <u>1,25(OH)₂D</u>	↑ Ca ²⁺ reabsorption	↑ Ca ²⁺
		Indirectly ↑ Ca ²⁺ , ↑ PO ₄ <u>absorption</u>	↓ PO ₄ reabsorption	↓ PO ₄
<u>1,25(OH)₂D</u>	Weak effect on <u>bone resorption</u>	↑ Ca ²⁺ , ↑ PO ₄ absorption	Weak effect on ↑ Ca ²⁺ reabsorption	↑ Ca ²⁺ , ↑ PO ₄
Calcitonin	↓ Bone resorption	No direct effects	↓ Ca ²⁺ , ↓ PO ₄ reabsorption	↓ Ca ²⁺ , ↓ PO ₄

Meng QH and Wagar EA. Crit Rev Clin Lab Sci 2015;52:107-19.



Causes of Hypercalcemia (1)

Preamanalytical errors:

Tourniquet use and venous occlusion: associated with increased-protein bound calcium: total calcium but not ionized calcium

Fist clenching or forearm exercise: decrease in pH and increase in ionized and total calcium

Hyperventilation: Respiratory alkalosis

Changes in posture: standing decreases intra-vascular water and increases protein and thus total calcium

Prolonged immobilization and bed rest: increase both total and ionized

Contamination with calcium: Corks, glassware, tubes, drywall

Analytical interference: Spectrophotometry (HIL) or ISE



Causes of Hypercalcemia (2) **AACC**

Better health through
laboratory medicine.

Clinical Causes of Hypercalcemia:

Parathyroid hormone

Primary hyperparathyroidism

Sporadic, familial, multiple endocrine neoplasia 1 (MEN 1) or MEN 2A

Secondary and Tertiary hyperparathyroidism

Coexisting malignancy and primary hyperparathyroidism

Ectopic PTH in malignancy (very rare)

Malignancy

Humoral hypercalcemia of malignancy

Parathyroid hormone-related protein (PTHrP)

Local osteolysis (mediated by cytokines) multiple myeloma,

Breast cancer, lung cancer - Modulated by Cytokines, chemokines, PTHrP

Vitamin D

Granulomatous disease: sarcoidosis, tuberculosis, berylliosis,

coccidioidomycosis: 1,25[OH]2D

Vitamin D intoxication

Vitamin D supplements, vitamin D metabolites or analogs

Lymphoma (1,25[OH]2D)



Causes of Hypercalcemia (3) AACCC

Better health through
laboratory medicine.

Renal Failure

Chronic renal failure with treatment with calcium and 1,25[OH]₂D or VitD analogs

Recovery phase of Rhabdomyolysis and acute renal failure

Renal transplant

Other Endocrine

Hyperthyroidism (Thyrotoxicosis)

Adrenal insufficiency

Acromegaly

Pheochromocytoma

Medications:

Thiazide diuretics

Lithium-related release of PTH

Milk–alkali syndrome (calcium and antacids)

Vitamin A intoxication

Theophylline

Other

Immobilization with high bone turnover (e.g., Paget's disease, bedridden patients)

Familial hypocalciuric hypercalcemia

Williams Syndrome

Hyperphosphatemia

Acute hypomagnesemia



In Reality...

- Primary hyperparathyroidism and cancer account for 90% of cases of hypercalcemia
- Outpatients
 - 90% have primary hyperparathyroidism
- Inpatients
 - 65% have cancer
 - 25% have primary hyperparathyroidism



Primary Hyperparathyroidism

- Increased calcium levels due to excessive PTH secretion from parathyroid adenoma (90%) or hyperplasia multiple gland enlargement (10%)
 - MEN 1
 - MEN 2A
 - Familial hyperparathyroidism
 - Carcinoma (<1%)
 - Familial benign hypercalcemia (FBH)
- Hypercalcemia results from combined effects of PTH-induced bone resorption, intestinal calcium absorption and renal tubular reabsorption
- Pathophysiology related to both PTH excess and concomitant excessive production of 1,25-(OH)₂-D.



Lab Tests in Diagnosis of Primary Hyperparathyroidism

- Intact PTH and chemistry panel
 - PTH elevated despite elevated serum calcium
 - Serum phosphate in the low-normal to mildly decreased range
 - Serum ALP increased, Hyperchloremic metabolic acidosis
- Urine calcium normal to slightly increase
- 24-hour urine calcium excretion
 - Used to rule out familial hypocalciuric hypercalcemia
 - Values below 100 mg/24 hours or a calcium creatinine clearance ratio of < 0.01 are suggestive of FHH
- Ionized calcium versus serum calcium: an age-old debate...
 - Corrected serum calcium
Serum calcium (mg/dL)+0.8 [4-albumin (g/dL)]



Mechanisms for Hypercalcemia of Malignancy

Underlying cause is generally excessive bone resorption by one of three mechanisms.

- Humoral hypercalcemia of malignancy: over-expression of PTH-related protein (PTHrP). PTHrP affects bone and kidney
 - Squamous cell carcinoma: lung, head and neck, esophagus, cervix, etc.
 - Carcinoma: ovarian, breast, renal, etc.
- 1,25-(OH)₂-D synthesis by lymphomas
- Local osteolytic hypercalcemia (cytokine-mediated) multiple myeloma
 - 20% of all hypercalcemia of malignancy



Laboratory Investigation of Hypercalcemia

Serum total calcium:

Ionized calcium: more accurate assessment of calcium status

Albumin: useful for corrected calcium

PTH:

25 (OH)vitamin D and 1,25 (OH)₂D:

Acid-base status

Electrolytes, Magnesium, Bicarbonate

Serum BUN and creatinine

Serum phosphate

Serum (urine) protein electrophoresis

Urinary calcium (24 hour), calcium to creatinine ratio

Urine creatinine

Urinary cyclic adenosine monophosphate (cAMP):

cAMP increased in primary hyperparathyroidism

PTHrP:



Laboratory Testing

Initial laboratory testing

- Total Calcium

Correct value if albumin decreased:

- Corrected Ca = Ca (mg/dl) + 0.8 (4-albumin [g/dl])

- If calcium elevated above 11.0 mg/dL – order intact PTH

- Ionized calcium

- Electrolytes– including BUN and creatinine

- Phosphorus



Laboratory Testing

➤ PTH (intact)

Elevated or normal – suggests hyperparathyroidism (elevated calcium should suppress PTH); order urine calcium (24-hour)

High – primary hyperparathyroidism

Low (<50-100 mg) – familial hypocalciuric hypercalcemia(FHH)

Low – order PTHrP or consider other testing for vitamin D excess, milk-alkali syndrome, hyperthyroidism

➤ PTHrP

Low or normal – order **vitamin D**: 25-(OH)D and 1,25-(OH)₂D

High – lymphoma or granulomatous disease (sarcoidosis, Wegener granulomatosis, Tuberculosis)

Low – consider testing for cancer

High – cancer




Additional Investigations:

- Chest X-ray: lung cancer or metastases, sarcoidosis, or tuberculosis
- Renal function: renal failure, milk-alkali syndrome, or renal impairment in primary hyperparathyroidism or myeloma
- Complete blood count: hematological malignancy or anemia
- Erythrocyte sedimentation rate or CRP: may be increased in cancer
- Serum alkaline phosphatase: may be increased in primary hyperparathyroidism, Paget's disease with immobilization, myeloma, or bone metastases
- Liver function tests: for liver metastases; chronic liver failure is also a rare cause of hypercalcemia.
- Thyroid function tests: Thyrotoxicosis
- Serum cortisol: Addison's disease is a rare cause.



Investigation of Hypercalcemia



Summary

- Primary hyperparathyroidism and cancer are the most common causes of hypercalcemia
- Intact PTH is the most important test in the differential diagnosis of hypercalcemia
- 24 hour urine calcium and calcium to creatinine ratio are helpful
- PTHrP should be measured if cancer is suspected
- Tests for other causes of hypercalcemia should be ordered for differential diagnosis
- An investigation algorithm should be established in each institution



References

1. Meng QH and Wagar EA. Laboratory approaches for the diagnosis and assessment of hypercalcemia. *Crit Rev Clin Lab Sci* 2015;52:107-19.
2. Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. *J Clin Endocrinol Metab* 2002;87:5353-61.
3. Burtis C, Ashwood E, and Bruns D. *Tietz Text Book* 2012, 5th edition

Disclosures/Potential Conflicts of Interest

Upon Pearl submission, the presenter completed the Clinical Chemistry disclosure form. Disclosures and/or potential conflicts of interest:

- **Employment or Leadership:**
- **Consultant or Advisory Role:**
- **Stock Ownership:**
- **Honoraria:**
- **Research Funding:**
- **Expert Testimony:**
- **Patents:**

*****This slide will be completed by CCJ Staff based on disclosure form completed electronically in the submission site.*****



Thank you for participating in this
Clinical Chemistry Trainee Council
Pearl of Laboratory Medicine.

Find our upcoming Pearls and other
Trainee Council information at
www.traineecouncil.org

Download the free *Clinical Chemistry* app
on iTunes today for additional content!

Follow us:

